INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Dice Therapeutics

Entrada Therapeutics

Zenas Biopharma

Star Therapeutics

Pyxis Oncology

Precision Biosciences

Orchard Therapeutics

Palvella Therapeutics

Carisma Therapeutics

Interius BioTherapeutics

Pliant Therapeutics

Skyhawk Therapeutics

Verge Genomics

ImCheck Therapeutics

Freenome

Dragonfly Therapeutics

Affini-T

View Full Portfolio

Featured News

Press Release | September 21, 2023

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Read More

News | September 20, 2023

ImCheck has been short-listed among the top 10 “Biotech et Medtech” companies for the 2023 edition of Les Trophées des Futures Licornes, which rewards the growth potential of innovative French companies.

Read More

Press Release | September 5, 2023

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

Read More

View All